APP
ACAD icon

Avantax Planning Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Avantax Planning Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2,020
Closed -$45K – 243
2018
Q1 		$45K Buy
+2,020
New +$55.9K ﹤0.01% 549

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Avantax Planning Partners's ACAD Position: Q2 2018 in Review

Avantax Planning Partners sold out of Acadia Pharmaceuticals (ACAD) in Q2 2018, closing a stake of 2,020 shares — an estimated $45K sold.

Avantax Planning Partners first reported a position in ACAD in Q1 2018 and held it in 1 quarter. The position peaked at $45K in Q1 2018. 187 funds tracked by Wall St. Rank hold ACAD as of Q2 2018.

  • Avantax Planning Partners reported no remaining Acadia Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Avantax Planning Partners sold 2,020 Acadia Pharmaceuticals shares in Q2 2018, an estimated $45K.
  • Avantax Planning Partners first reported a position in Acadia Pharmaceuticals in Q1 2018 and held it in 1 quarter.
  • Avantax Planning Partners's Acadia Pharmaceuticals position peaked at $45K in Q1 2018.
  • 187 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2018.

Based on Avantax Planning Partners's 13F filing for Q2 2018, filed 13 Aug 2018.